Literature DB >> 12599234

Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers.

Maria P Wong1, Lai-Fan Fung, Elaine Wang, Wing-Shun Chow, Shui-Wah Chiu, Wah-Kit Lam, Kwok-Keung Ho, Edmond S K Ma, Thomas S K Wan, Lap-Ping Chung.   

Abstract

BACKGROUND: Lung carcinoma is a common malignancy, and tobacco carcinogenesis is the major cause. Studies on individual genes or loci have suggested, that in tumors from nonsmokers, different genetic alterations are present compared with tumors from smokers. It is possible that distinct genetic pathways may be involved. However, the targets remain largely unknown; and, to the authors' knowledge, molecular cytogenetics studies on lung carcinomas from nonsmokers have not been reported.
METHODS: Comparative genomic hybridization (CGH) analysis was performed on primary lung adenocarcinoma samples from 32 patients who never smoked to identify loci of frequent aberrations.
RESULTS: Different extents of aberration were found in 31 of the 32 samples studied. The most frequently altered locus was gain of 16p (59% of samples) followed by gain of 20q (44% of samples), with the minimal overlapping regions at 16p13.1-p13.2 and 20q13.2, respectively. Other over-represented loci with > 30% frequency were observed at 5p (34% of samples), 7p (41% of samples), 8q (31% of samples), 17q (34% of samples), and 19q (34% of samples); and high-level DNA amplifications were detected at 1q, 7p, 12q, 19q, and 20q. DNA under-representation was observed less commonly and included 8p (28% of samples), 9p (22% of samples), 13q (28% of samples), and 18q (38% of samples).
CONCLUSIONS: The current study identified targets of frequent genetic aberration in primary adenocarcinomas from nonsmokers. Compared with reported CGH findings in the literature, the current findings suggest that DNA gain at 16p is the distinct aberration involved in these tumors. Other frequently altered loci involve commonly reported oncogenic and tumor suppressor loci, suggesting an overlap with the genetic pathways of tobacco-induced lung carcinogenesis. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12599234     DOI: 10.1002/cncr.11183

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

1.  Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis.

Authors:  Hannah O'Farrell; Bryant Harbourne; Zimple Kurlawala; Yusuke Inoue; Amy L Nagelberg; Victor D Martinez; Daniel Lu; Min Hee Oh; Bradley P Coe; Kelsie L Thu; Romel Somwar; Stephen Lam; Wan L Lam; Arun M Unni; Levi Beverly; William W Lockwood
Journal:  J Thorac Oncol       Date:  2018-12-19       Impact factor: 15.609

2.  A novel role for hSMG-1 in stress granule formation.

Authors:  James A L Brown; Tara L Roberts; Renee Richards; Rick Woods; Geoff Birrell; Y C Lim; Shigeo Ohno; Akio Yamashita; Robert T Abraham; Nuri Gueven; Martin F Lavin
Journal:  Mol Cell Biol       Date:  2011-09-12       Impact factor: 4.272

3.  miR-151-5p modulates APH1a expression to participate in contextual fear memory formation.

Authors:  Xu-Feng Xu; You-Cui Wang; Liang Zong; Xiao-Long Wang
Journal:  RNA Biol       Date:  2019-01-29       Impact factor: 4.652

4.  Lung cancers unrelated to smoking: characterized by single oncogene addiction?

Authors:  Kenichi Suda; Kenji Tomizawa; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Int J Clin Oncol       Date:  2011-06-08       Impact factor: 3.402

5.  PDRG1, a novel tumor marker for multiple malignancies that is selectively regulated by genotoxic stress.

Authors:  Lingyan Jiang; Xiuquan Luo; Jingxue Shi; Hong Sun; Qing Sun; M Saeed Sheikh; Ying Huang
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

Review 6.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

7.  A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.

Authors:  Yosef Buganim; Ido Goldstein; Doron Lipson; Michael Milyavsky; Sylvie Polak-Charcon; Corine Mardoukh; Hilla Solomon; Eyal Kalo; Shalom Madar; Ran Brosh; Marina Perelman; Roy Navon; Naomi Goldfinger; Iris Barshack; Zohar Yakhini; Varda Rotter
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

8.  Genomic aberrations in lung adenocarcinoma in never smokers.

Authors:  Bastien Job; Alain Bernheim; Michèle Beau-Faller; Sophie Camilleri-Broët; Philippe Girard; Paul Hofman; Julien Mazières; Saloua Toujani; Ludovic Lacroix; Julien Laffaire; Philippe Dessen; Pierre Fouret
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

9.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Authors:  Rhamy Zeid; Matthew A Lawlor; Evon Poon; Jaime M Reyes; Mariateresa Fulciniti; Michael A Lopez; Thomas G Scott; Behnam Nabet; Michael A Erb; Georg E Winter; Zoe Jacobson; Donald R Polaski; Kristen L Karlin; Rachel A Hirsch; Nikhil P Munshi; Thomas F Westbrook; Louis Chesler; Charles Y Lin; James E Bradner
Journal:  Nat Genet       Date:  2018-01-29       Impact factor: 38.330

10.  Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms.

Authors:  Xia Xu; Jennifer L Page; Jennifer A Surtees; Houchun Liu; Sarah Lagedrost; Young Lu; Roderick Bronson; Eric Alani; Alexander Yu Nikitin; Robert S Weiss
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.